Head to Head Analysis: Heyu Biological Technology (OTCMKTS:HYBT) and Arvinas (NASDAQ:ARVN)

Arvinas (NASDAQ:ARVN) and Heyu Biological Technology (OTCMKTS:HYBT) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

Profitability

This table compares Arvinas and Heyu Biological Technology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Arvinas	2.94%	1.91%	1.29%
Heyu Biological Technology	-453.55%	-6.43%	-4.43%

Volatility & Risk

Arvinas has a beta of 1.75, suggesting that its stock price is 75% more volatile than the S&P 500. Comparatively, Heyu Biological Technology has a beta of -17.74, suggesting that its stock price is 1,874% less volatile than the S&P 500.

Insider & Institutional Ownership

95.2% of Arvinas shares are owned by institutional investors. 7.3% of Arvinas shares are owned by insiders. Comparatively, 89.2% of Heyu Biological Technology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Arvinas and Heyu Biological Technology”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arvinas	$262.60 million	2.29	-$80.80 million	$0.10	93.10
Heyu Biological Technology	$80,000.00	129.19	-$270,000.00	N/A	N/A

Heyu Biological Technology has lower revenue, but higher earnings than Arvinas.

Analyst Ratings

This is a breakdown of recent recommendations for Arvinas and Heyu Biological Technology, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arvinas	2	3	5	1	2.45
Heyu Biological Technology	0	0	0	0	0.00

Arvinas presently has a consensus price target of $14.17, indicating a potential upside of 52.17%. Given Arvinas’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Arvinas is more favorable than Heyu Biological Technology.

Summary

Arvinas beats Heyu Biological Technology on 10 of the 13 factors compared between the two stocks.

About Arvinas

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

About Heyu Biological Technology

Hong Chang Biotechnologies (HK) Limited was incorporated in 2023 and is based in Kowloon, Hong Kong. Hong Chang Biotechnologies (HK) Limited operates as a subsidiary of Zengqiang Investment Limited. As of September 4, 2023, Hong Chang Biotechnologies (HK) Limited operates as a subsidiary of Heyu Biological Technology Corporation.